Talecris Biotherapeutics, Inc. (TBI) announced the merger of Precision Pharma Services, a wholly-owned subsidiary of Talecris, into TBI. Talecris’ parent company acquired Precision Pharma of Melville, NY in 2005, maintaining its name and separate operations.
    
Precision’s 140 employees will become Talecris employees and will remain in Melville. Precision Pharma provides manufacturing and testing services to the biotechnology and pharmaceutical industries. These services include aseptic filling and product manufacturing ranging from plasma fractionation to pharmaceutical compounding to separation, extraction, concentration and purification of complex molecules.
   
“Since the acquisition, the people and facility in Melville have been critical to our manufacturing process by significantly increasing our fractionation capacity and contract services business,” said Mary Kuhn, senior vice president of operations for Talecris Biotherapeutics. “This merger combines the Melville facility’s expertise with the Talecris Clayton facility’s expertise to continue our commitment to the patient communities who rely on our products.”
   
“The Precision Pharma culture is rooted in performance and continuous improvement — two qualities that define the Talecris business model,” said Frank Sauers, senior director, Melville Operations. “By operating under one brand, we can truly realize the vision of global market leadership in product innovation, quality, and safety.”